Do pharma and biotech investors encourage companies indulging in ‘patent thicket?’ This question recently grabbed media headlines. On April 02, 2019, one such report brought out: AbbVie investors are calling for the Chair-CEO power split, flagging the CEO’s USD 4 million bonus payout, fueled … Continue reading
Tag Archives: IPO
For Drug Safety Concern: “Whistleblower’s Intention Should Be Nationalistic”
In the recent weeks, three significant developments related to the Pharmaceutical Industry in India, have triggered rejuvenated concerns in the following critical areas: A. Overall drug safety standards in the country B. Self serving interest, rather than patients’ interest, dominate … Continue reading
The Curious Imbroglio: Innovation, IPR, India and ‘Uncle Sam’
Last week, the Office of the United States Trade Representative (USTR) released the “2015 Special 301 Report”, which is its annual review of the global state of Intellectual Property Rights (IPR) protection and enforcement. While looking through the Kaleidoscope of … Continue reading
Awaiting ‘The Moment of Truth’ on ‘Working of Patents’ in India
By a letter dated October 21, 2014 addressed to the Secretary, Department of Industrial Policy and Promotion (DIPP) of India, the domestic pharma major Cipla has sought for the revocation of five patents of Novartis AG’s respiratory drug Indacaterol (Onbrez) in India, … Continue reading
MNCs to Challenge MNC Patents in India: Boon for Patients?
Close on the heels of a reasonably successful patent challenge by the German pharma Multinational Corporation (MNC) Fresenius Kabi for the breast cancer drug Tykerb of GlaxoSmithKline (GSK) in India, another MNC Mylan, with its headquarter in the United states, … Continue reading
India, China Revoke Four Pharma Patents in A Fortnight: A Double Whammy for MNCs?
Revocation of four pharma patents by India and China within a fortnight has raised many eyebrows, yet again, across the globe. In this short period, India has revoked three patents and China one. While this quick development is probably a … Continue reading
Does the Landmark Glivec Judgment Discourage Innovation in India?
No, I do not think so. The 112 pages well articulated judgment of the Supreme Court of India delivered on April 1, 2013, does not even remotely discourage innovation in India, including much talked about ‘incremental innovation’. This landmark judgment … Continue reading
Government Ups the Ante for More Compulsory Licenses in India
On January 12, 2013, one of the leading dailies of India first reported that in a move that is intended to benefit thousands of cancer patients, Indian Government has started the process of issuing Compulsory Licenses (CL) for three commonly … Continue reading